NSCLC

Biomarkers

The diagnosis of NSCLC typically involves a combination of radiological and pathological assessment.1​​ After a NSCLC diagnosis, comprehensive biomarker testing is crucial in identifying an appropriate patient care plan for the unique characteristics of a patient and their disease.2,3

To obtain samples for diagnostic testing, pulmonologists use several biopsy methods, including EBUS- and CT-guided procedures. Following diagnosis, these samples undergo testing to identify actionable biomarkers that can guide the use of targeted therapies.3-5​​​

Actionable AND EMERGING Biomarkers

The biomarkers shown here are actionable and emerging and may be tested in metastatic NSCLC.5,6

Protein Expression6,7

c-Met (MET)

PD-L1

HER2

Genomic Profiling6,8-12

EGFR mutation

KRAS mutation

METex14 skipping mutation

Learn more

BRAF V600E mutation

ERBB2 mutation

NRG1 gene fusion

ALK rearrangement

RET rearrangement

ROS1 rearrangement

NTRK1/2/3 gene fusion

FGFR mutation

MET focal gene amplification

Learn more
IHC
NGS and/or PCR
FISH
Early-stage testing also advised
Emerging biomarkers
The biomarkers listed are not comprehensive and may not include all biomarkers available for testing. This may include biomarkers that are emerging.
ALK=anaplastic lymphoma kinase; BRAF=B-raf proto-oncogene, serine/threonine kinase; CAP=College of American Pathologists; c-Met/MET=mesenchymal-epithelial transition; CT=computed tomography; EBUS=endobronchial ultrasound; EGFR=epidermal growth factor receptor; ERBB2=erb-b2 receptor tyrosine kinase 2; ESMO=European Society for Medical Oncology; ex14=exon 14; FGFR=fibroblast growth factor receptor; FISH=fluorescence in situ hybridization; HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; KRAS=Kirsten rat sarcoma virus; NCCN=National Comprehensive Cancer Network; NGS=next-generation sequencing; NRG1=neuregulin 1; NSCLC=non-small cell lung cancer; NTRK1/2/3=neurotrophic receptor tyrosine kinase 1/2/3; PCR=polymerase chain reaction; PD-L1=programmed cell death protein ligand 1; RET=ret proto-oncogene; ROS1=ros proto-oncogene, receptor tyrosine kinase.

Learn more about MET in NSCLC
References
    1. National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version. Accessed August 12, 2025. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. 2. Hirsch FR, Kim C. Oncol Ther. 2024;12(2):223-231. doi:10.1007/s40487-024-00271-w. 3. Lim C, et al. Ann Oncol. 2015;26(7):1415-1421. doi:10.1093/annonc/mdv208. 4. Diep R, et al. JTO Clin Res Rep. 2023;4(4):100497. doi:10.1016/j.jtocrr.2023.100497. 5. Qin K, et al. Cancers (Basel). 2023;15(3):612. doi:10.3390/cancers15030612. 6. Baron JM, et al. JCO Precis Oncol. 2024;8:e2400039. doi:10.1200/PO.24.00039. 7. Sierra JR, Tsao MS. Ther Adv Med Oncol. 2011;3(1 Suppl):S21-S35. doi:10.1177/1758834011422557. 8. Xu J, et al. Am J Clin Oncol. 2024;47(6):291-303. doi:10.1097/COC.0000000000001088. 9. Shih JY. J Thorac Oncol. 2024;19(5):668-670. doi:10.1016/j.jtho.2024.02.001. 10. Gupta B, et al. Lung Cancer (Auckl). 2024;15:143-148. doi:10.2147/LCTT.S464626. 11. Qin A, et al. J Thorac Oncol. 2019;14(1):54-62. doi:10.1016/j.jtho.2018.09.014. 12. Yin W, et al. Cancers (Basel). 2022;14(10):2433. doi:10.3390/cancers14102433.
    References
    1. Remon J, Hendriks LEL, Mountzios G, et al. J Thorac Oncol. 2023;18(4):419-435. doi:10.1016/j.jtho.2022.10.015.
    2. Han Y, Yu Y, Miao D, et al. JTO Clin Res Rep. 2024;5(2):100630. doi:10.1016/j.jtocrr.2023.100630.
    3. Altintas DM, Comoglio PM. Cancers (Basel). 2023;15(18):4672. doi:10.3390/cancers15184672.
    4. Liang H, Wang M. Onco Targets Ther. 2020;13:2491-2510. doi:10.2147/OTT.S231257.
    5. Park S, Choi YL, Sung CO, et al. Histol Histopathol. 2012;27(2):197-207. doi:10.14670/HH-27.197.
    6. Sun W, Song L, Ai T, et al. J Biomed Res. 2013;27(3):220-230. doi:10.7555/JBR.27.20130004.
    7. Socinski MA, Pennell NA, Davies KD. JCO Precis Oncol. 2021;5:PO.20.00516. doi:10.1200/PO.20.00516.
    8. Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV. J Hematol Oncol. 2021;14(1)129. doi:10.1186/s13045-021-01138-7.
    9. Sierra JR, Tsao MS. Ther Adv Med Oncol. 2011;3(1 Suppl):S21-35. doi:10.1177/1758834011422557.
    10. Yin W, Guo M, Tang Z, et al. Cancers (Basel). 2022;14(10):2433. doi:10.3390/cancers14102433.
    11. Ding C, Qiu Y, Zhang J, et al. BMC Pulm Med. 2023;23(1):240. doi:10.1186/s12890-023-02482-9.
    12. Coleman N, Hong L, Zhang J, et al. ESMO Open. 2021;6(6):100319. doi:10.1016/j.esmoop.2021.100319.
    13. Settleman J. Curr Biol. 2012;22(2):R43-4. doi:10.1016/j.cub.2011.11.004.
    14. Qin K, Hong L, Zhang J, et al. Cancers (Basel). 2023;15(3):612. doi:10.3390/cancers15030612.
    15. Hartmaier RJ, Markovets AA, Ahn MJ, et al. Cancer Discov. 2023;13(1):98-113. doi:10.1158/2159-8290.CD-22-0586.
    16. Xiang C, Lv X, Chen K, et al. Mod Pathol. 2024;37(4):100451. doi:10.1016/j.modpat.2024.100451.
    17. Heydt C, Ihle MA, Merkelbach-Bruse S. Cancers (Basel). 2023;15(11):2932. doi:10.3390/cancers15112932.
    18. Mazieres J, Vioix H, Pfeiffer BM, et al. Clin Lung Cancer. 2023;24(6):483-497. doi:10.1016/j.cllc.2023.06.008.
    19. Reischmann N, Schmelas C, Molina-Vila MA, et al. iScience. 2023;26(7);107006. doi:10.1016/j.isci.2023.107006.
    20. Friedlaender A, Drilon A, Banna GL, et al. Cancer. 2020;26(22):4826-4837. doi:10.1002/cncr.33159.
    This website is for healthcare professionals inside the United States only and is provided for informational purposes only.
    Developed and authored by AbbVie US Medical Affairs.
    © 2026 AbbVie Inc. All rights reserved.
    ABBV-US-02264-MC, v1.0
    Approved: January 2026
    All AbbVie product names appearing in this internet site are trademarks owned by or licensed by AbbVie Inc., its subsidiaries or affiliates. All other trademarks are the property of their respective owners. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without AbbVie's prior written authorization, except to identify the product or services of the company.
    Accessibility Statement Medical Information Terms of Use Contact Us Privacy Notice Cookies Settings
    Your Privacy Choices